
Cantargia Q2 2023: CAN10 Approaching the Clinic

Redeye comments on Cantargia's second quarter report 2023. An application to start a clinical trial with the second project, CAN10, was submitted and approved since our last update.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Cantargia Q2 2023: CAN10 Approaching the Clinic](#)